EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH SEROPOSITIVE POLYARTHRITIS FROM RISK GROUP OF TUBERCULOSIS INFECTION

EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH SEROPOSITIVE POLYARTHRITIS FROM RISK GROUP OF TUBERCULOSIS INFECTION

A short review on modern views on abatacept usage in treatment of juvenile idiopathic arthritis is shown in this article with highlighting of the high safety of this drug in accordance with severe opportunistic infections, including tuberculosis. The authors also discuss possibility of its usage in...

Full description

Bibliographic Details
Main Authors: L. A. Balykova, N. V. Shchekina, A. V. Krasnopol’skaya, T. I. Kornilova, N. A. Os'kina
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2013-12-01
Series:Voprosy Sovremennoj Pediatrii
Subjects:
abatacept
juvenile idiopathic polyarthritis
tuberculosis
Online Access:https://vsp.spr-journal.ru/jour/article/view/270
Description
Summary:A short review on modern views on abatacept usage in treatment of juvenile idiopathic arthritis is shown in this article with highlighting of the high safety of this drug in accordance with severe opportunistic infections, including tuberculosis. The authors also discuss possibility of its usage in cases of inefficiency (intolerability) of tumor necrosis factor alpha in combination with methotrexate or as monotherapy. A history case of abatacept treatment of polyarticular type of juvenile idiopathic arthritis with risk factors of unfavorable outcome, severe associated disease and latent tuberculosis infection is demonstrated.
ISSN:1682-5527
1682-5535

Similar Items